Research Analysts Set Expectations for THTX FY2025 Earnings

Theratechnologies Inc. (NASDAQ:THTX) – Equities research analysts at Leede Financial cut their FY2025 EPS estimates for Theratechnologies in a report released on Wednesday, February 26th. Leede Financial analyst D. Loe now anticipates that the company will earn $0.06 per share for the year, down from their prior estimate of $0.07. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2026 earnings at $0.15 EPS.

Separately, Research Capitl raised shares of Theratechnologies to a “strong-buy” rating in a research report on Friday, February 14th.

Theratechnologies Stock Performance

Shares of THTX stock opened at $1.62 on Thursday. Theratechnologies has a fifty-two week low of $1.08 and a fifty-two week high of $2.18. The stock has a 50 day simple moving average of $1.74 and a two-hundred day simple moving average of $1.45. The company has a market cap of $74.49 million, a P/E ratio of -16.20 and a beta of 1.26.

Hedge Funds Weigh In On Theratechnologies

Several institutional investors have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. bought a new stake in Theratechnologies in the 4th quarter valued at about $108,000. National Bank of Canada FI grew its stake in Theratechnologies by 29.4% in the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after acquiring an additional 42,435 shares during the period. Virtu Financial LLC bought a new stake in shares of Theratechnologies during the fourth quarter valued at approximately $40,000. BNP Paribas Financial Markets acquired a new position in shares of Theratechnologies during the fourth quarter worth approximately $36,000. Finally, Wealthspire Advisors LLC raised its position in shares of Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock worth $129,000 after purchasing an additional 20,000 shares during the period.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.